Circadian rhythm disturbances in depression

Objective The aim of this article is to review progress in understanding the mechanisms that underlie circadian and sleep rhythms, and their role in the pathogenesis and treatment of depression. Methods Literature was selected principally by Medline searches, and additional reports were identified b...

Full description

Saved in:
Bibliographic Details
Published inHuman psychopharmacology Vol. 23; no. 7; pp. 571 - 585
Main Authors Germain, Anne, Kupfer, David J.
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.10.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective The aim of this article is to review progress in understanding the mechanisms that underlie circadian and sleep rhythms, and their role in the pathogenesis and treatment of depression. Methods Literature was selected principally by Medline searches, and additional reports were identified based on ongoing research activities in the authors' laboratory. Results Many physiological processes show circadian rhythms of activity. Sleep and waking are the most obvious circadian rhythms in mammals. There is considerable evidence that circadian and sleep disturbances are important in the pathophysiology of mood disorders. Depressed patients often show altered circadian rhythms, sleep disturbances, and diurnal mood variation. Chronotherapies, including bright light exposure, sleep deprivation, and social rhythm therapies, may be useful adjuncts in non‐seasonal and seasonal depression. Antidepressant drugs have marked effects on circadian processes and sleep. Conclusions Recent progress in understanding chronobiological and sleep regulation mechanisms may provide novel insights and avenues into the development of new pharmacological and behavioral treatment strategies for mood disorders. Copyright © 2008 John Wiley & Sons, Ltd.
Bibliography:Dr Germain received financial support from Servier for the preparation of this manuscript. Dr Kupfer has served on advisory boards of Eli Lilly and Company, Forest Pharmaceuticals, Inc., Pfizer, Inc., and Solvay/Wyeth Pharmaceuticals and also served as a consultant for Servier.
istex:F1BA012A484F73862C5042A477B634CF5AE28A10
ArticleID:HUP964
ark:/67375/WNG-QLVMJ7X5-4
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0885-6222
1099-1077
1099-1077
DOI:10.1002/hup.964